Brittni Scruggs
Ophthalmology · Rochester, MNNPI 1942689252
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,760 of the $21,350 with a category attached, or 83.2%. Astellas Pharma US Inc accounts for 84.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $18,000 and has fallen 93.9% since, to $1,099 in 2024. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $1779.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$18K
- Genentech, Inc.$2K
- Spark Therapeutics, Inc.$1K
- Alimera Sciences, Inc.$350
- Janssen Global Services, LLC$114
- Alcon$94
What the payments were for
- Consulting fees$17,76083%
- Speaking & faculty fees$2,35011%
- Travel & lodging$8554%
- Food & beverage$3852%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $18,000 |
| Genentech, Inc. | 1 | $1,760 |
| Spark Therapeutics, Inc. | 6 | $1,032 |
| Alimera Sciences, Inc. | 1 | $350 |
| Janssen Global Services, LLC | 1 | $114 |
| Alcon | 1 | $94 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,350 in reported general payments places this provider in the 95th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 39 | $1,467 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 31 | $411 |
| Dorzolamide Hcl | 15 | $266 |
| Latanoprost | 29 | $236 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Rochester
- Sophie BakriRochester$183K
- John ChenRochester$82K
- Raymond IezziRochester$44K
- Arthur SitRochester$33K
- Muhammad BhattiRochester$24K
- Sanjay PatelRochester$20K
- Matthew StarrRochester$16K
- Lilly WagnerRochester$15K
- John WoogRochester$6K
- James GarrityRochester$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.